COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02797704
Recruitment Status : Terminated (the treatment was found to be inefficient for all recruited patients)
First Posted : June 13, 2016
Last Update Posted : September 16, 2019
Information provided by (Responsible Party):
Rabin Medical Center

Brief Summary:
The goal of this current study is to prospectively evaluate the influence of a single subconjunctival aflibercept injection on the regression of corneal neovascularization. Twenty patients with corneal neovascularization who are candidates for anti VEGF treatment (by the discretion of a corneal specialist) will be included in this study. The patients will be treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single quarter of the conjunctiva, near the limbus in a proximity to the area of pathological neovascularization. Regression of neovascularization will be documented.

Condition or disease Intervention/treatment Phase
Corneal Neovascularization Drug: Aflibercept Phase 1 Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of Subconjunctival Aflibercept on Regression of Corneal Neovascularization
Actual Study Start Date : March 2, 2017
Actual Primary Completion Date : September 4, 2019
Actual Study Completion Date : September 10, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: SC Aflibercept
The patients will be treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single quarter of the conjunctiva, near the limbus in a proximity to the area of pathological neovascularization
Drug: Aflibercept
Eylea (aflibercept) Injection is a prescription medicine administered by injection into the eye.
Other Name: Eylea

Primary Outcome Measures :
  1. Regression (change from baseline) of neovascularization clinically assessed by a corneal specialist [ Time Frame: 3 months (90 days), with repeat assessment at different follow up times at 7,14,30,60 and 90 days. ]
    Regression of corneal neovascularization as the change from baseline will be assessed at all follow-up times on days 7,14,30,60,90 following injection by the corneal specialist, both by a clinical slit lamp exam to evaluate the area of neovascularization from the entire corneal area (which will be determined clinically by the ophthalmologist), and by performing anterior segment color photography before injection and at the last visit for comparison and documentation purposes.

Secondary Outcome Measures :
  1. Best Corrected Visual Acuity (BCVA) [ Time Frame: 3 months ]
    BCVA will be assessed using a Snellen Chart at all follow-up meetings, and converted to logMAR for statistical analysis.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

In this study, included will be patients with corneal neovascularization secondary to various pathologies, including: Pterygium, Corneal chemical burn, S/P corneal transplantation, Herpetic keratitis, atopic keratoconjunctivitis, Chronic retinal detachment, Uveitis, panus secondary to blepharitis, S/P corneal foreign body.

Exclusion Criteria:

  1. Patients with a history of retinal vein/artery occlusion or diabetes, currently treated with anti-VEGF or with a history of such treatment 3 months prior to enrollment.
  2. Prior treatment for corneal neovascularization with the injection of Avastin/Lucentis.
  3. Patients under 18
  4. Pregnant women
  5. Contra indications for Eylea treatment, including intraocular or periocular infection/inflammation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02797704

Layout table for location information
Rabin Medical Center
Petah Tikva, Israel
Sponsors and Collaborators
Rabin Medical Center
Layout table for investigator information
Principal Investigator: Irit Bahar, MD Head of ophthalmology department

Publications of Results:
Other Publications:

Layout table for additonal information
Responsible Party: Rabin Medical Center Identifier: NCT02797704    
Other Study ID Numbers: 0134-16-RMC
First Posted: June 13, 2016    Key Record Dates
Last Update Posted: September 16, 2019
Last Verified: May 2016

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Corneal Neovascularization
Neovascularization, Pathologic
Pathologic Processes
Corneal Diseases
Eye Diseases